OncoSpan reference standards

Have confidence in your cancer assay

Optimize your validation or monitor assay performance with OncoSpan

Take advantage of a renewable, reproducible, and highly characterized reference control material providing consistency from assay development to routine monitoring.

Highly multiplexed reference control panel containing over 370 variants across 152 oncogenes, including >27 indels
Cell line derived control material is commutable to patient samples
Develop, troubleshoot and assess bioinformatics performance with a companion high coverage, batch specific in silico NGS data set
Available as cell-free DNA, FFPE curls, and genomic DNA
Range of allele frequencies enable rapid determination of LOD in your assay and sensitivities
Demonstrated repeatability and reproducibility with an R2 correlation coefficient in NGS ranging from 0.95 to 0.97 for all OncoSpan formats

OncoSpan applications

Enable novel cancer assay development
Conduct routine monitoring of assay performance and data analysis

Utilize NGS controls to calibrate your assays

Improve patient selection for clinical trials
Develop early cancer detection methods
Assess therapeutic efficacy

OncoSpan publications

Read these research articles citing the use of OncoSpan reference standards.

Validation of a pan-cancer targeted next generation sequencing panel in New Zealand | New Zealand Journal of Medical Laboratory Science
Enabling variant calling in challenging FFPE samples by coupling a novel library preparation chemistry with exome sequencing | Journal of Clinical Oncology
Moving towards a local testing solution for undetermined thyroid fine-needle aspirates: validation of a novel custom DNA-based NGS panel | Journal of Clinical Pathology
Performance Analysis of Three Bioinformatic Variant Callers Using a Somatic Reference Standard | Children's Mercy Kansas City

For assay developers and molecular diagnostic labs for routine performance monitoring of molecular biology assays. Research use only. Not for diagnostic procedures.